EUCTR2013-001325-24-CZ进行中（未招募）1 期
A randomized, open-label, parallel group, multi-center Phase II clinicaltrial evaluating effect of addition of DCVAC/OvCa to standardchemotherapy in women with relapsed platinum resistant epithelialovarian carcinoma
SOTIO a.s.0 个研究点目标入组 60 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female aged =18 years
- •Patients with histologically confirmed, FIGO (Féderation Internationale
- •de Gynécologie et d’Obstétrique) stage III epithelial ovarian, primary
- •peritoneal, or fallopian tube carcinoma (serous, endometrioid or
- •mucinous), who have undergone initial or interval debulking surgery
- •but have not reached complete remission of more than 6 months after
- •first line Platinum (Pt) based chemotherapy, for one of the following
- •Patients are Pt-refractory (no response)
- •Complete remission was not reached (partial responders)
- •Relapse within =6 months of remission (Pt-resistant)
- •Pt-based chemotherapy failure should have been confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) scan (Pt-resistant) or by finding described as ‘did not reach complete clinical remission’ (Pt-refractory or Pt-partial response)
- •Patients must have at least one measureable target lesion as defined by
- •the RECIST 1.1 criteria
- •Laboratory criteria (results must be obtained <14 days before randomization, including results obtained before giving informed consent):
- •White blood cells (WBC) >4,000/mm3 (4.0 x109/L)
- •Neutrophil count >1,500/mm3 (1.5 x109/L)
- •Hemoglobin of at least 10g/dL (100g/L)
- •Platelet count of at least 100,000/mm3 (100 x109/L)
- •Total bilirubin within normal limits (benign hereditary hyperbilirubinaemias, e.g. Gilbert´s syndrome are permitted)
- •Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2x upper limit of normal (ULN), serum
- •creatinine =2.0mg/dL
- •Blood Urea Nitrogen (BUN) <2.0x ULN
- •Adequate coagulation parameters (results must be obtained <14 days before randomization, including results obtained before giving
- •informed consent):
- •Activated partial thromboplastin time (APTT) =1.5x ULN and
- •International Normalized Ratio (INR) =1.5
- •Life expectancy of at least 12 months based on Investigators judgment
- •Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- •Signed informed consent including patient’s ability to comprehend its
- •Females of childbearing potential must have had a negative serum
- •pregnancy test at screening (ß-human chorionic gonadotropin [ß-HCG])
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •FIGO I,II,IV epithelial ovarian cancer
- •FIGO III clear cells epithelial ovarian cancer
- •Non-epithelial ovarian cancer
- •Borderline tumors (tumors of low malignant potential)
- •Prior or current systemic anti-cancer therapy for ovarian cancer (for example chemotherapy, monoclonal antibody therapy , tyrosine kinase inhibitor therapy, vascular endothelial growth factor [VEGF] therapy or hormonal therapy) except first line Pt-based chemotherapy (with or without bevacizumab)
- •Previous radiotherapy to the abdomen and pelvis
- •Malignancy other than epithelial ovarian cancer, except those that have
- •been in CR for a minimum of 3 years, and except carcinoma in-situ of
- •the cervix or non-melanoma skin carcinomas
- •Patient co-morbidities:
- •Human immunodeficiency virus (HIV) positive, human
- •T-lymphotropic virus (HTLV) positive
- •Active hepatitis B (HBV), active hepatitis C (HCV), active
- •Evidence of active bacterial, viral or fungal infection requiring
- •systemic treatment
- •Clinically significant cardiovascular disease including:
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •serious cardiac arrhythmia requiring medication
- •Uncontrolled hypertension
- •Myocardial infarction or ventricular arrhythmia or stroke
- •within a 6 month period before inclusion, ejection fraction
- •(EF) <40% or serious cardiac conduction system
- •disorders, if a pacemaker is not present Pleural and pericardial effusion of any National Cancer Institute
- •(NCI) common terminology criteria for adverse events (CTCAE)
- •Peripheral neuropathy having a CTCAE =Grade 2
- •Active autoimmune disease requiring treatment
- •History of severe forms of primary immune deficiencies
- •History or anaphylaxis or other serious reaction following
- •vaccination
- •Uncontrolled co-morbidities including, psychiatric or social
- •conditions which, in the Investigator’s opinion, would prevent
- •participation in the trial
- •Known hypersensitivity to any constituent in the DCVAC/OvCa
- •Systemic immunosuppressive therapy for any reason
- •Refusal to sign the informed consent
- •Participation in a clinical trial using experimental therapy within the
- •last 4 weeks before study entry; patients previously enrolled in protocol
- •SOV01 who did not receive treatment with DCVAC/OvCa can be
- •included in this study
- •Fertile woman of childbearing potential not willing to use adequate
- •contraception for the study duration and at least six months afterwards
- •Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with relapsed platinum sensitive ovarian carcinomaepithelial ovarian carcinomaMedDRA version: 18.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001323-38-DESOTIO a.s.60
进行中（未招募）
1 期
Evaluation and efficacy and safety of DCVAC/OvCa (ovarian cancerimmunotherapy) in woman with relapsed platinum resistant epithelial ovarian carcinomaEUCTR2013-001325-24-PLSOTIO a.s.60
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with relapsed platinum sensitive ovarian carcinomaEUCTR2013-001323-38-PLSOTIO a.s.60
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with relapsed platinum sensitive ovarian carcinomaepithelial ovarian carcinomaMedDRA version: 19.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001323-38-CZSOTIO a.s.60
进行中（未招募）
1 期
Evaluation and efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in woman with relapsed platinum resistant epithelial ovarian carcinomaepithelial ovarian carcinomaMedDRA version: 18.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001325-24-DESOTIO a.s.60